# Pavadi Capital LLC

> Institutional holdings reported to the SEC as of Q4 2023 on Form 13F. CIK 1906649. Source: https://holderbook.com/funds/1906649-pavadi-capital-llc/

- Reported value: $81.2M
- Positions: 14
- Weight of the ten largest: 82.6%
- Filed: 2024-02-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| ELEVANCE HEALTH INC FORMERLY | [ELV](https://holderbook.com/stocks/ELV/) | $8.2M | 17,374 | 10.1% | 1 |
| UNITEDHEALTH GROUP INC | [UNH](https://holderbook.com/stocks/UNH/) | $8.0M | 15,271 | 9.9% | 9 |
| HCA HEALTHCARE INC | [HCA](https://holderbook.com/stocks/HCA/) | $7.6M | 27,927 | 9.3% | 9 |
| MOLINA HEALTHCARE INC | [MOH](https://holderbook.com/stocks/MOH/) | $6.9M | 19,079 | 8.5% | 9 |
| CENTENE CORP DEL | [CNC](https://holderbook.com/stocks/CNC/) | $6.9M | 92,349 | 8.4% | 9 |
| CVS HEALTH CORP | [CVS](https://holderbook.com/stocks/CVS/) | $6.8M | 85,580 | 8.3% | 9 |
| ZIMMER BIOMET HOLDINGS INC | [ZBH](https://holderbook.com/stocks/ZBH/) | $6.8M | 55,515 | 8.3% | 1 |
| HUMANA INC | [HUM](https://holderbook.com/stocks/HUM/) | $6.4M | 13,878 | 7.8% | 9 |
| BAXTER INTL INC | [BAX](https://holderbook.com/stocks/BAX/) | $5.1M | 131,315 | 6.3% | 1 |
| PATTERSON COS INC | [PDCO](https://holderbook.com/stocks/PDCO/) | $4.6M | 160,155 | 5.6% | 3 |
| GE HEALTHCARE TECHNOLOGIES I | [GEHC](https://holderbook.com/stocks/GEHC/) | $4.4M | 56,560 | 5.4% | 2 |
| QUIDELORTHO CORP | [QDEL](https://holderbook.com/stocks/QDEL/) | $3.7M | 50,752 | 4.6% | 3 |
| TENET HEALTHCARE CORP | [THC](https://holderbook.com/stocks/THC/) | $3.5M | 46,433 | 4.3% | 9 |
| LANTHEUS HLDGS INC | [LNTH](https://holderbook.com/stocks/LNTH/) | $2.5M | 40,492 | 3.1% | 5 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q4 2023 | +3.2% | +11.2% | -7.9% | 100% |
| Q3 2023 | -8.3% | -3.6% | -4.7% | 100% |
| Q2 2023 | +6.1% | +8.3% | -2.1% | 100% |
| Q1 2023 | -3.2% | +7.0% | -10.2% | 100% |
| Q4 2022 | +8.5% | +7.1% | +1.4% | 100% |
| Q3 2022 | -4.0% | -5.3% | +1.4% | 100% |
| Q2 2022 | -14.4% | -16.5% | +2.0% | 100% |
| Q1 2022 | -3.9% | -4.9% | +1.0% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q4 2023 | $81.2M | 14 |
| Q3 2023 | $76.8M | 16 |
| Q2 2023 | $85.7M | 15 |
| Q1 2023 | $91.6M | 16 |
| Q4 2022 | $106.1M | 18 |
| Q3 2022 | $104.4M | 23 |
| Q2 2022 | $110.3M | 22 |
| Q1 2022 | $113.5M | 25 |
| Q4 2021 | $131.8M | 22 |